In our study, CTS, the novel NPC1L1 inhibitor, significantly alleviated hepatic steatosis in HFD-fed mice, indicating that the therapeutic effect of CTS against NAFLD may be regulated by inhibiting NPC1L1-mediated intestinal cholesterol absorption. This evidence concerns the gene NPC1L1 and fatty liver disease.